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ABSTRACT
Homing endonucleases have become valuable
tools for genome engineering. Their sequence rec-
ognition repertoires can be expanded by modify-
ing their specificities or by creating chimeric
proteins through domain swapping between two
subdomains of different homing endonucleases.
Here, we show that these two approaches can be
combined to create engineered meganucleases with
new specificities. We demonstrate the modularity of
the chimeric DmoCre meganuclease previously
described, by successfully assembling mutants
with locally altered specificities affecting both
I-DmoI and I-CreI subdomains in order to create
active meganucleases with altered specificities.
Moreover these new engineered DmoCre variants
appear highly specific and present a low toxicity
level, similar to I-SceI, and can induce efficient
homologous recombination events in mammalian
cells. The DmoCre based meganucleases can there-
fore offer new possibilities for various genome engi-
neering applications.
INTRODUCTION
The last 15 years have seen the emergence of new reagents
enabling precise genome engineering (1–6). Among these
new tools are the engineered homing endonucleases, also
known as meganucleases, recognizing long DNA
sequences (12–45bp). In nature, these proteins are
encoded by mobile introns or inteins, which propagate
by cleaving the cognate allele from which the mobile
element is absent, thereby stimulating the duplication of
the mobile element into the recipient locus by a mecha-
nism of DSB-induced homologous recombination.
Mimicking this strategy to manipulate genes by targeted
recombination has long been used in many laboratories
and has proven to be robust and eﬃcient (7,8).
However, until recently, meganuclease-induced recombi-
nation was limited to the repertoire of natural
meganucleases available which considerably impaired its
potential applications. Indeed, the cognate DNA target of
natural meganucleases is not necessarily present in a given
genome and as a prerequisite prior to tinkering with a
gene of interest, it has to be introduced into the desired
locus.
Meganucleases are divided into ﬁve diﬀerent families,
from which the LAGLIDADG proteins, named after the
short consensus LAGLIDADG sequence, constitute the
largest and probably the best characterized family. The
catalytic site is located within the center of the relatively
compact molecule which confers a tight connection
between cleavage and DNA-binding activities. Several
protein structures including I-CreI, I-MsoI, I-AniI or
I-SceI have been solved in complex with their DNA
target (9–12) and could be engineered to change their
speciﬁcity (13–16). Recently, we described a new protein
engineering strategy using the modular architecture of the
LAGLIDADG proteins. We showed that ﬁrst, by altering
the speciﬁcity locally (17) and then by adopting a
combinatorial strategy (18), it was possible to redesign
the I-CreI meganuclease speciﬁcity towards a chosen
DNA sequence (18,19). Ultimately, I-CreI derived
meganucleases could be used successfully to induce eﬃ-
cient targeted recombination in endogenous genes (2).
Thus, these new tools oﬀer the possibility to manipulate
a genome in a very precise and safe manner.
Monomeric meganucleases could represent the best
reagent for gene targeting applications as they alleviate
the problems associated with the delivery and coordinated
expression of two molecules needed with dimeric proteins
such as I-CreI. The generation of active single-chain
meganucleases has been previously reported, for example
with I-CreI and I-MsoI, two homodimeric proteins that
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domain swapping between the two subdomains of
I-DmoI and between I-DmoI and I-CreI was also shown
(20,22,23). Recently, Grizot et al. (2) showed that a single-
chain I-CreI variant, targeting the human endogenous
RAG1 locus, was potentially safer than the original
heterodimeric molecule as it abolished the formation
of the homodimer by-products, generated by the
co-expression of the two monomers.
In this article, we applied a combinatorial approach to
engineer the chimeric DmoCre protein and successfully
modiﬁed its speciﬁcity. The protein activity was ﬁrst
increased to eventually match the activity of natural
meganucleases like I-CreI or I-SceI in mammalian cells,
while maintaining a high speciﬁcity and low toxicity.
Taking advantage of the thousands of I-CreI mutants
available in our data base, we then showed that I-CreI
mutants could be introduced by domain shuﬄing into
the DmoCre molecule. In parallel, variants with altered
speciﬁcity within the I-DmoI moiety of the molecule
were produced and assembled with I-CreI variants in
order to create entirely new DmoCre variants. Finally,
we show that engineered DmoCre meganucleases show
very high speciﬁcities, similar to the parental DmoCre
scaﬀold or the natural I-SceI meganuclease, as no toxic
eﬀect could be detected in a cell survival assay or in a
g-H2AX foci formation assay. Thus, the DmoCre
meganuclease variants appear to represent a new molecu-
lar tool in the genome engineering toolbox.
MATERIALS AND METHODS
Construction of target clones
The diﬀerent 22-bp DNA targets that were used in the
yeast screening assay were cloned as follows.
Oligonucleotides containing the target site (Proligo) were
ampliﬁed by PCR to generate double-stranded target
DNA. The PCR products were then inserted into
reporter vectors with the Gateway protocol (Invitrogen):
the yeast vector pFL39-ADH-LACURAZ and the mam-
malian vector pcDNA3.1-LAACZ, both previously
described and containing an I-SceI target site as a
control. Yeast reporter vectors were used to transform
Saccharomyces cerevisiae strain FYBL2-7B (MATa,
ura3851, trp163, leu21, lys2202).
Meganuclease production
The ORFs encoding the various meganucleases were
ampliﬁed by PCR and inserted into the 2 micron-based
replicative vector pCLS542, harboring the LEU2 gene.
Saccharomyces cerevisiae strain FYC2-6A (MATa,
trp163, leu21, his3200) was then transformed with
the vector using a high-eﬃciency lithium acetate transfor-
mation protocol. For expression in mammalian cells, the
various meganuclease genes were also inserted into the
mammalian vector pcDNA3.1. The genes were expressed
under the control of a CMV promoter. Some of the
proteins were also cloned with the addition of an HA
(YPYDVPDYA) epitope into the C-terminus of the
proteins which does not aﬀect protein expression levels
or activities.
Incorporation of I-CreI speciﬁc mutations into the
DmoCre scaﬀold
In order to generate DmoCre derived coding sequences
that contain mutations in the I-CreI moiety of the
protein, a PCR reaction was carried out that ampliﬁes
the region between residues 13–148 for each of the
I-CreI derived cutters. The diﬀerent PCR fragments
were then pooled. The yeast expression vector for the
DmoCre protein was then digested with NgoMIV and
MluI removing a fragment covering residues 111–238 of
the DmoCre protein. Finally, 25ng of the PCR pool and
75ng of the digested vector DNA were used to transform
the yeast S. cerevisiae strain FYC2-6A (MAT , trp163,
leu21, his3200) using a high-eﬃciency LiAc transfor-
mation protocol. An intact DmoCre coding sequence con-
taining the mutations characteristic of the diﬀerent I-CreI
mutants was generated by in vivo homologous recombina-
tion in yeast.
Construction of DmoCre mutant libraries
DmoCre mutant libraries randomized at positions 29, 33
and 35 (D10C1lib library) or 75, 76 and 77 (D4C1lib) or
41, 75 and 77 (D4bisC1lib) were constructed using NNK
degenerate codons resulting in a theoretical protein diver-
sity of 8000 (20
3) as previously described (17). All libraries
were generated by in vivo homologous recombination in
yeast into the pCLS542 vector.
Mating of meganuclease expressing clones and
screening in yeast
A colony gridder (QpixII, Genetix) was used for the
mating of yeast strains. Mutants were gridded on nylon
ﬁlters placed on YPGlycerol plates, using high gridding
density ( 20 spots/cm
2). A second gridding process was
performed on the same ﬁlters for spotting of a second
layer consisting of reporter-harboring yeast strains for
each target. Membranes were placed on solid agar con-
taining YPGlycerol rich medium, and incubated overnight
at 30 C, to allow mating. The ﬁlters were then transferred
onto synthetic medium, lacking leucine and tryptophan,
with glucose (2%) as the carbon source (and with G418
for coexpression experiments) and incubated for 5 days at
30 C, to select for diploids carrying the expression and
target vectors. Finally, ﬁlters were transferred onto
YPGalactose rich medium for 2 days at 37 C to induce
the expression of the meganuclease. Filters were then
placed on solid agarose medium with 0.02% X-Gal in
0.5M sodium phosphate buﬀer, pH 7.0, 0.1% SDS, 6%
dimethyl formamide (DMF), 7mM b-mercaptoethanol,
1% agarose and incubated at 37 C, to monitor
b-galactosidase activity. Filters were scanned and each
spot was quantiﬁed using the median values of the
pixels constituting the spot. We attribute the arbitrary
values 0 and 1 to respectively white and dark pixels.
b-Galactosidase activity is directly associated with the eﬃ-
ciency of homologous recombination (17).
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Error-prone PCR was used to introduce random muta-
tions in a pool of chosen mutants. Libraries were
generated by error-prone PCR using Mn
2+ at a concen-
tration of 0.3mM (24,25). To maintain a relatively low
rate of mutagenesis, the concentrations of dCTP and
dTTP were not increased. Under these conditions, the
analysis of the resulting protein sequences showed that
half of the molecules were not mutated, while the other
half of the mutants carried 1.4 mutations on average. In
addition, 60% of the amino acid was mutated at least once
in the library.
Extrachromosomal assay in CHO-K1 cells
CHO-K1 cells were transfected with the meganuclease
expression vectors and the reporter plasmid, in the
presence of Polyfect transfection reagent in accordance
with the manufacturer’s protocol (Qiagen). The culture
medium was removed 72h after transfection and 150ml
of lysis/detection buﬀer was added for b-galactosidase
liquid assay [typically, for 1l of buﬀer, we used 100ml
of lysis buﬀer (10mM Tris–HCl, pH 7.5, 150mM NaCl,
0.1% Triton  100, 0.1mg/ml BSA, protease inhibitors),
10ml of Mg 100 buﬀer (MgCl2 100mM,
2-mercaptoethanol 35%), 110ml of an 8mg/ml solution
of ONPG and 780ml of 0.1M sodium phosphate pH 7.5].
After incubation at 37 C, we measured optical density at
420nm. The entire process was performed on 96-well plate
format using an automated Velocity11 BioCel platform.
Conditions have been adapted so that the cell number and
transfection eﬃciency are constant in every wells through
out the plates. To insure repeatability and reproducibility
of the experiments, control plates are included in all
plates. Correlation between intra- and inter-plates
controls allows us to validate the assay.
Targeting of a chromosomal reporter gene in
CHO-K1 cells
The introduction of diﬀerent meganuclease sites in the
same chromosomal context has already been described
(19). Brieﬂy, a transgene containing an I-SceI cleavage
site has been stably expressed in CHO-K1 cells in single
copy. In order to create a cell line containing the
meganuclease target site, the cells were cotransfected
with an I-SceI expression vector and a repair plasmid con-
taining a LacZ expression cassette interrupted by the
meganuclease site. In a second step, the CHO-K1 cell
lines harboring the reporter system were seeded at a
density of 2 10
5 cells per 10cm dish in complete
medium [Kaighn’s modiﬁed F-12 medium (F12-K), sup-
plemented with 2mM L-glutamine, penicillin (100IU/ml),
streptomycin (100mg/ml), amphotericin B (Fongizone)
(0.25mg/ml) (Invitrogen-Life Science) and 10% FBS
(Sigma-Aldrich Chimie)]. The next day, cells were
cotransfected in the presence of Polyfect transfection
reagent (Qiagen) with 2mg of LacZ repair matrix vector
and various amounts of meganuclease expression vector.
After 72h of incubation at 37 C, b-galactosidase activity
was measured using the Beta-Glo Assay System
(Promega). The signal value is plotted against a standard
curve established by measuring the luminescent signal
emitted by a mixed LacZ+/LacZ  cell population. The
frequency of LacZ positive cells is expressed as a percent-
age and is calculated using the standard curve and cor-
rected for the transfection eﬃciency.
Cell survival assay
The CHO-K1 cell line was used to seed plates at a density
of 2 10
5 cells per 10cm dish. The next day, various
amounts of meganuclease expression vectors and a
constant amount of GFP-encoding plasmids were used
to transfect the cells. GFP levels were monitored on
days 1 and 6 after transfection, by ﬂow cytometry
(Guava EasyCyte, Guava Technologies). Cell survival is
expressed as a percentage and was calculated as a ratio:
(meganuclease-transfected cell expressing GFP on day
6/control transfected cell expressing GFP on day 6) cor-
rected for the transfection eﬃciency determined on day 1.
c-H2AX immunocytochemistry
For g-H2AX immunocytochemistry, CHO-K1 cells were
transfected with a mixture containing 1mg of plasmid
encoding a HA-tagged meganuclease and with DNA
levels totaling up to 4.5mg with empty vector, in the
presence of Polyfect reagent (Qiagen). Cells were ﬁxed
48h after transfection, by incubation with 2% of
paraformaldehyde for 20min and permeabilized by incu-
bation for 5min at room temperature in 0.5% Triton.
Cells were washed and incubated for 1h in 0.3% Triton
buﬀer supplemented with 10% normal goat serum (NGS)
and 3% BSA, to block non-speciﬁc staining. Cells were
then incubated for 1h at RT with anti-g-H2AX (Upstate:
1/10000) and anti-HA (Santa Cruz:1/700) antibodies
diluted in Triton 0.3% in PBS supplemented with 3%
BSA and 10% NGS and then for 1h with Alexa Fluor
546 goat anti-mouse (Invitrogen-Molecular Probes:
1/1000) and Alexa Fluor 488 goat anti-rabbit secondary
antibodies (Invitrogen-Molecular Probes 1/1000) diluted
in 0.3% Triton in PBS supplemented with 3% BSA and
10% NGS. Coverslips were incubated with 1mg/ml
40,6-diamino-20-phenylindole (DAPI, Sigma) mounted
and the g-H2AX foci were visualized in transfected cells
(HA-positive) by ﬂuorescence microscopy. The inactive
I-CreI V2(G19S)/V3(G19S) heterodimer was used as a
negative control at a dose of 1mg for each expression
plasmid.
RESULTS
Activity improvement and characterization of the hybrid
DmoCre protein
We previously described the engineering of a chimeric
DmoCre meganuclease (20) resulting from the fusion of
the N-terminal domain of I-DmoI with one I-CreI
monomer (Figure 1a) able to cleave the combined
D2-C1 target (Figure 1b). Due to the hyperthermophilic
2008 Nucleic Acids Research, 2010,Vol.38, No. 6origin of I-DmoI, the DmoCre protein was functional at a
high temperature on the D2-C1 target but displayed a
modest in vivo activity in living cells (data not shown).
In order to improve the cleavage activity of the DmoCre
protein, two rounds of random mutagenesis using
error-prone PCR were performed on the I-DmoI half of
the DmoCre coding sequence. Following the ﬁrst round of
optimization, we identiﬁed a variant carrying the G20S
mutation that showed maximum cleavage activity
toward the D2-C1 target using our previously described
yeast assay (20). However, as shown in Figure 1c, this
mutant displayed a very low level of activity using an
extrachromosomal single-strand annealing (SSA) assay
in CHO-K1 cells (17). A second round of mutagenesis
was thus performed on the DmoCre G20S variant. Two
thousand two hundred mutants were screened for high
level of activity in CHO-K1 cells. The protein with the
highest activity (Figure 1c), called DmoCreV5, displayed
three mutations located in the LAGLIDADG helix of the
I-DmoI moiety: L15Q, I19D and G20S (the protein
(a)
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Figure 1. The DmoCre protein. (a) Representation of the chimeric protein DmoCre. The N-terminal domain of I-DmoI (residues 1–109) is depicted
in blue and the I-CreI monomer (residues 13–163) in brown. (b) Nomenclature used for various of DNA targets. C1C1 is the palindromic target
derived from the I-CreI target. The 10NNN (±8,±9,±10nt) and 5NNN (±3,±4,±5nt) regions of the target are boxed. D2D1 is the I-DmoI
target. D2-C1 is the target cleaved by the hybrid DmoCre protein. (c) In vivo activity.of optimized DmoCre. DmoCre variants with improved activity
were ﬁrst characterized by an extrachromosomal assay in CHO-K1 cells. Cells were transfected with meganuclease or empty vector and the resulting
cleavage was monitored against the three targets described in (b). Activity of I-SceI against its natural S1234 target is shown as a positive control.
Activity of the meganuclease DmoCreV5 was also monitored in a chromosomal gene conversion assay in CHO-K1 cells. CHO-K1 cells containing a
single chromosomal copy of the lacZ gene interrupted by the DNA target site were co-transfected with increasing amounts of the meganuclease
expression vector and a ﬁxed quantity of the lacZ repair plasmid. Activity of the DmoCreV5 and I-SceI meganucleases was monitored using two
diﬀerent cell lines that diﬀer only by the meganuclease target site (D2-C1 for DmoCre and S1234 for I-SceI).
Nucleic Acids Research,2010, Vol.38, No. 6 2009sequence is provided in the Supplementary Material). In
order to estimate the full potential of the newly generated
DmoCreV5 meganuclease, the protein activity was
assessed using a chromosomal gene targeting assay that
has already been described (19). Brieﬂy, a CHO-K1 strain
carrying a single copy of the lacZ gene interrupted by the
D2-C1 target was produced. Subsequently, cells were
cotransfected with increasing amounts of plasmid coding
for the DmoCreV5 protein and a ﬁxed quantity of plasmid
carrying a truncated LacZ gene as a repair matrix.
Cleavage of the D2-C1 target by the DmoCreV5
endonuclease results in the restoration of the LacZ gene
by gene conversion and thus production of active
b-galactosidase. The frequency of LacZ positive cells
was measured 72h post-transfection. Figure 1c shows
that the new DmoCreV5 protein can induce gene correc-
tion in up to 0.8% of transfected cells and has an activity
proﬁle very similar to I-SceI.
Insertion of I-CreI derived mutants into the DmoCre
scaﬀold
In addition to its monomeric architecture, the DmoCre
scaﬀold oﬀers the possibility to use I-CreI derived
mutants that have already been obtained and
characterized (17–19). Therefore, we then tested whether
the I-DmoI and I-CreI moities could be modiﬁed
independently. In order to answer this question, we
used a subset of I-CreI mutants with new substrate
speciﬁcities towards either nucleotides located at posi-
tions±10,±9,±8 (10NNN) or at positions±5,±4,±3
(5NNN) of the palindromic I-CreI target C1C1
(Figure 1b) or I-CreI variants generated by a combina-
torial process and able to cleave 10NNN-5NNN hybrid
targets (18). These I-CreI derived mutants were incorpo-
rated into the DmoCreV5 coding sequence by in vivo
cloning in yeast (see ‘Material and methods’ section) and
activity of the resulting DmoCre variants was monitored
in yeast against the corresponding target. Table 1 summa-
rizes the data. The cleavage activity is expressed as an
arbitrary value between 0 and 1. In all cases, active
DmoCre variants could be obtained, showing the
relative independence of the two domains of the protein.
Although most of the resulting DmoCre mutants showed
a cleavage activity similar to the corresponding I-CreI
mutants, the introduction of the I-CreI mutants targeting
the Ca or the Cb DNA sequences within the DmoCreV5
protein resulted in a relatively low success rate for the
combinatorial process (respectively 17 and 24%) and
in a slight loss of cleavage activity of the active
variants. We then optimized these proteins in order to
increase their cleavage activities on D2-Ca or D2-Cb
targets. For each target, a corresponding pool of three
active DmoCre mutants (Table 2, #1, #2, #3 and #4, #5,
#6) was used as a template in error-prone PCR, covering
the entire length of the molecule. Two thousand
two hundred and thirty two (2232) clones generated
by in vivo cloning in yeast were then screened against
the target of interest. For both D2-Ca and D2-Cb
targets, highly active proteins could thus be obtained
(Figure 2a).
Two improved meganucleases, Va and Vb (Table 2),
speciﬁc to D2-Ca and D2-Cb respectively, were selected
for further activity analyses in mammalian cells. The
ORF’s were further subcloned into a mammalian expres-
sion vector and their activity was determined in our
extrachromosomal SSA assay in CHO-K1 cells.
Figure 2b shows the activity of the original DmoCreV5
meganuclease and the two selected DmoCre variants
tested against all three targets (D2-C1, D2-Ca and
D2-Cb). Each meganuclease showed speciﬁc cleavage of
its cognate target. Interestingly, the analysis of the mutant
sequences revealed that the mutations introduced during
error-prone PCR aﬀected only the I-CreI moiety of the
molecule (Table 2). While one additional mutated
position (Y163H) was found in the Va variant cleaving
Table 1. Cleavage activity of DmoCre variants with altered speciﬁcity within the I-CreI moiety
Targets derived from C1221 that
are cleaved by I-CreI mutants
a
Number and strength
of the I-CreI mutants
Targets cleaved by DmoCre mutants
a,
number of positive DmoCre mutants
and maximal cleavage activity
CAAAACTTGGTACCAAGTTTTG 16
0.11<AU<0.30
CGCCGGAACTTACCAAGTTTTG
16
AUmax=0.56
CAAAACGAGGTACCTCGTTTTG 36
0.2<AU<1.0
CGCCGGAACTTACCTCGTTTTG
32
AUmax=0.92
CCCAACGTCGTACGACGTTGGG1 4
0.15<AU<0.70
CGCCGGAACTTACGACGTTGGG
12
AUmax=0.92
CTGGCTGCTGTACAGCAGCCAG2 6
0.61<AU<0.94
CGCCGGAACTTACAGCAGCCAG
19
AUmax=0.89
CGTTCTCAGGTACCTGAGAACG (Ca)
33
0.4<AU<1.0
CGCCGGAACTTACCTGAGAACG (D2-Ca)
8
AUmax=0.40; (0.91)
b
CTGGCTGAGGTACCTCAGCCAG (Cb)
35
0.2<AU<0.74
CGCCGGAACTTACCTCAGCCAG ( D2-Cb)
6
AUmax=0.48; (0.97)
b
AU: arbitrary unit.
aBases bold underlined are bases for which the I-CreI speciﬁcity has been modiﬁed.
bCleavage activity after protein optimization.
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Figure 2. In vivo activity of DmoCre variants with altered speciﬁcity in the I-CreI moiety. (a) Yeast secondary screening of optimized DmoCre
mutants toward respectively the D2-Ca and D2-Cb targets. The optimized mutants displayed on the two yeast ﬁlters had already been selected based
on a cleavage activity equivalent or greater than the initial activity level during a primary screening. For each target, one optimized mutant is located
in the two left dots on each four-dot yeast cluster. The bottom right dot represents internal experimental controls (negative or positive) while the
upper right dot is one of the DmoCre mutants that have been used as a template for the optimization process (respectively mutant #2 for the D2-Ca
target and mutant #6 for the D2-Cb target, Table 2). The Va and Vb mutants have been circled. For both targets, the nucleotides in the C1 part of
the D2-C1 target for which the speciﬁcity has been modiﬁed are in red. (b) Extrachromosomal assay in CHO-K1 cells. Cells were transfected with
diﬀerent meganucleases or an empty vector and the cleavage against the D2-Ca, D2-Cb and D2-C1 targets was monitored.
Table 2. Sequences of engineered DmoCre variants
D R B FNAKNYQSQYRRDI VI
Target Mutant 75 77 93 101 102 108 125 127 130 135 137 141 163 165 167 172 174 202 229
D2-Ca #1 KA A YS YK
#2 RC A YS YK
#3 RC A YS R
Va RC AHYS YK
D2-Cb #4 Q S RRT S Y
#5 N S RRY S QV
#6 N S RRA NN
Vb Q S RRA NQV
D(4AGT)-C1 S1 RV
D(4AGT)-Ca M 1 R V RC AHYS YK
M2 RN S R C A H Y S Y K
M3 R A RC AHYS YK
OM 1 RN L R C A H Y S Y K V
OM 2 R N S E RC AHYS YK
OM 3 RN S R C A H Y S Y K A
D(4AGT)-Cb P 1 R A Q S RRA NQV
P2 Y V Q S RRA NQV
P3 T C Q S RRA NQV
OP 1 T C S Q S RRA NQV V
OP 2 R A Q S RRA NQV V
Nucleic Acids Research,2010, Vol.38, No. 6 2011the D2-Ca target, the improved mutant Vb, speciﬁc to the
D2-Cb target, appears to result from a shuﬄing of the
mutations present on the three initial DmoCre variants
during the error-prone PCR step.
Functionally engineered meganucleases with new speciﬁties
toward the D2 portion of the D2-C1 target
The I-CreI domain of the DmoCre scaﬀold can be easily
shuﬄed with I-CreI derived mutants already available.
However, the engineering of the protein–DNA interface
of the Dmo part of the molecule would considerably
expand its potential application. Therefore we tried to
locally alter the DNA speciﬁcity of the I-DmoI moiety
of the molecule. The structure of I-DmoI and E-DreI, a
meganuclease very similar to our DmoCre protein, have
been resolved alone or in complex with their DNA target
(23,26,27). The E-DreI protein is slightly diﬀerent from
the DmoCre protein, but these diﬀerences do not involve
residues in direct contact with the DNA or in close prox-
imity. Moreover, the I-DmoI subdomain, common to the
E-DreI and I-DmoI proteins, has been described as having
the same protein–DNA interaction pattern (27). Thus the
analysis of the I-DmoI structure brought us to divide the
D2 part of the D2-C1 target into three triplets: 10NNN
(bases at positions  10,  9 and  8), 7NNN (bases at
position  7,  6 and  5) and 4NNN (bases at positions
 4,  3 and  2) (Figure 3b). Analysis of the E-DreI
structure leads to similar hypothesis. For each
degenerated triplet, the corresponding 64 DNA targets
were produced [D(10NNN)-C1, D(7NNN)-C1 and
D(4NNN)-C1] and several DmoCre mutant libraries
were generated in yeast.
In order to create a DmoCre library targeting the group
of D(10NNN)-C1 targets, the residues Tyr29, Arg33 and
Glu35 of the protein were randomized. 2232 clones, rep-
resenting 28% of the library diversity, were screened
against the 64 D(10NNN)-C1 targets. Three hundred
and eighty seven active mutants with unique sequences
were thereby identiﬁed. Figure 3a shows that the
DmoCreV5 protein is able to cleave 16 out of the 64
targets, ﬁve of which were very faintly cleaved. The
protein exhibits a low speciﬁcity toward the base at
position  10 as it is able to cleave the four D(NCC)-C1
targets. The whole collection of newly produced DmoCre
variants allowed cleavage for 50 out of 64 D(10NNN)-C1
targets (Figure 3b). Moreover, with an average of six
targets cleaved per variant, these engineered
meganucleases appeared to retain a speciﬁcity equivalent,
if not higher than, the DmoCreV5 protein.
Using the same strategy, the residues Asp75, Thr76 and
Arg77 of the protein were randomized in order to generate
a DmoCreV5 library targeting the DNA triplet at posi-
tions  4,  3 and  2 of D2-C1 (D(4NNN)-C1). The
screening of the library (2232 clones) against the 64
D(4NNN)-C1 DNA targets yielded 570 active mutants
with unique sequences. Six D(4NNN)-C1 targets were
cleaved by the initial DmoCreV5 protein (Figure 3a)
while 23 out of the 64 D(4NNN)-C1 DNA triplets were
recognized by the new DmoCre variants (Figure 3b).
Furthermore these mutants appear highly speciﬁc since
the average number of tolerated targets is three targets
per protein. We noticed that the D(4ANN)-C1 sequences
were preferentially targeted by the library (Figure 3b). As
an example of this engineering step, a mutant called S1
speciﬁc for the D(4AGT)-C1 target and carrying the
D75R and R77V mutations was chosen and cloned into
a mammalian expression vector for further characteriza-
tions. Analysis of the E-DreI and I-DmoI structures in
complex with their DNA targets show that the residue
Thr41 makes a van der Waals contact with the methyl
group of the complementary strand containing a
thymidine at position  4. Therefore, we generated a
new library randomized at residues Thr41, Asp75 and
Arg77, while keeping the Thr76 ﬁxed to limit the diversity
of the library. Screening against the D(4NNN)-C1 targets
allowed the isolation of 221 unique mutants which cleaved
an average of two targets. In addition to the 35
D(4NNN)-C1 sequences recognized by at least one
mutant, the randomization of the residue Thr41 allowed
the cleavage of new D(4GNN)-C1 and D(4TNN)-C1
targets. Still, almost no cleavage for the D(4CNN)-C1
targets could be detected.
The analysis of the E-DreI and I-DmoI structures
shows that Arg37 and Arg81 interact extensively with
the nucleotides at positions  7,  6 and  5 of the
D2-C1 target and appear resistant to engineering since
mutations in any of the arginines led either to an
inactive protein or to a protein with much reduced
activity (data not shown). However, the original
DmoCreV5 meganuclease tolerates a purine at positions
 7 and  6 and does not display strong speciﬁcity at
position  5. Overall, DmoCre V5 is able to cleave 9 out
of the 64 D(7NNN)-C1 DNA targets in our yeast assay
(Figure 3a).
Combination of two mutations sets in the I-DmoI
subdomain
Hundreds of DmoCre mutants recognizing the
D(10NNN)-C1 or D(4NNN)-C1 targets have been
obtained. We have previously described for the I-CreI
protein, how to combine two mutation sets by a
combinatorial approach to generate engineered I-CreI
mutants (18). We then decided to apply this approach to
the I-DmoI subdomain of DmoCre. The two sets of muta-
tions Tyr29, Arg33, Glu35, and Asp75, Thr76, Arg77,
constitute two distinct groups of mutations, which could
therefore be combined into the same DmoCre coding
sequence. Four D(10NNN)-C1 targets were selected
(D(10CAG)-C1, D(10CCA)-C1, D(10CCG)-C1,
D(10GCG)-C1), together with 24 corresponding
DmoCre variants for each target. The same procedure
was performed for three D(4NNN)-C1 targets where
three sets of 24 DmoCre mutants recognizing respectively,
D(4AGA)-C1, D(4AGT)-C1 and D(4ATA)-C1 DNA
sequences, were chosen. Finally, the two groups of muta-
tions were combined by in vivo cloning in yeast. Eight
mutant libraries were created in such a manner and
screened against their corresponding combined targets.
None of the libraries enabled us to detect active proteins
2012 Nucleic Acids Research, 2010,Vol.38, No. 6(data not show). This result prompted us to adopt an
alternative approach in which the two mutation sets
would be introduced sequentially. Thus, a pool of eight
DmoCre variants cleaving the D(4AGT)-C1 target was
selected as a template to generate a mutant library
randomized at residues Tyr29 and Arg33. The residue
Glu35 was ignored in order to maintain the diversity
of the library. The library was then screened
against four combined targets [D(10GCG4AGT)-C1,
D(10CCG4AGT)-C1 and D(10CAG4AGT)-C1,
D(10CCA4AGT)-C1]. No active protein cleaving the
ﬁrst three targets could be detected, but 13 unique
proteins were able to cleave the D(10CCA4AGT)-C1
target, albeit with a low eﬃciency. Four mutants were
further selected as templates in an error-prone PCR exper-
iment in order to improve the cleavage activity. Although
D(10NNN)-C1
(a)
D(4NNN)-C1
(b)
D(10NNN)-C1
D(4NNN)-C1
D(7NNN)-C1
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(Asp75, Thr76, Arg77) (Thr41, Asp75, Arg77)
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Figure 3. Proﬁling of the DmoCre protein on DNA targets deriving from D2-C1. (a) The D2 part of the D2-C1 target has been subdivided into
three diﬀerent domains: the 10, 9, 8 triplet (D(10NNN)-C1), the 7, 6, 5 triplet (D(7NNN)-C1) and the 4, 3, 2 triplet (D(4NNN)-C1].
For each DNA triplet, the DmoCreV5 protein has been proﬁled in yeast against the 64 corresponding degenerated targets. The gray level is
proportional to the cleavage intensity obtained with DmoCreV5 in yeast. (b) Hitmaps of diﬀerent DmoCreV5 mutant libraries that were screened
in yeast. The number of identiﬁed active proteins is shown below each target and the gray level is proportional to the average signal intensity
obtained with these cutters in yeast. Amino acids that were randomized are indicated on top of the hitmaps. See Supplementary Data for statistical
analysis.
Nucleic Acids Research,2010, Vol.38, No. 6 2013their endonuclease activities could be improved, these
mutants did not reach the level of I-SceI activity in
yeast, and no activity could be detected using our
extrachromosomal assay in CHO-K1 cells (data not
shown).
Combination of mutation sets present in both I-DmoI and
I-CreI subdomains
To explore the engineering possibilities of the DmoCre
molecule, we assembled mutations aﬀecting the speciﬁcity
of both the I-DmoI and I-CreI moieties. The improved
meganucleases Va and Vb, speciﬁc to D2-Ca and D2-Cb
were selected and used as templates to generate I-DmoI
libraries randomized at residues Tyr29, Arg33, Glu35, or,
Asp75, Thr76, Arg77. The four resulting libraries were
then screened in yeast against 18 randomly chosen
hybrid targets. Table 3 summarizes the results, conﬁrming
that the modularity between the I-DmoI and I-CreI
subdomains as active DmoCre variants could be
obtained against 13 out of the 18 tested targets.
DmoCre variants, able to cleave the D(4AGT)-Cb and
D(4AGT)-Ca targets (Figure 4a and b), were further
selected for in vivo activity characterization. For each
target, a pool of three mutants, M1 to M3 and P1 to P3
(Table 2), showing good activity on their respective targets
in yeast, were selected and their activities further
improved. Upon random mutagenesis, new optimized
variants, OM1 to OM3, and OP1, OP2, displaying high
cleavage activities against D4(AGT)-Ca or D(4AGT)-Cb,
respectively, were chosen and cloned into a mamma-
lian expression vector in order to perform an
extrachromosomal recombination assay in CHO-K1
cells. Figure 4a and 4b show that all the DmoCre
variants tested were active in CHO-K1 cells. However,
the engineering step that shifts the protein speciﬁcity
from the D2-Ca or D2-Cb target to D(4AGT)-Ca or
D(4AGT)-Cb, respectively, also reduced, to a certain
extent, the mutant cleavage activity which could be par-
tially recovered after our optimization step. Importantly,
the newly obtained DmoCre mutants are speciﬁc for their
targets as they display no cleavage activity towards the
D2-Ca or D2-Cb targets (Figure 4a and b). Analysis of
mutant sequences conﬁrmed that activity improvements
resulted mainly in the addition of mutations in residues
located in the I-CreI moiety of the DmoCre molecule or in
the region linking the two subdomains (residues 93–108)
(Table 2). In agreement with previous data (28), the
C-terminal part of the I-CreI protein seems to play a
major role in DmoCre activity since mutations aﬀecting
this domain (amino acids 202 and 229) can increase
cleavage eﬃcacy in living cells. The residues Val202 and
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Figure 4. Activity of DmoCre mutants with altered speciﬁcity in both
I-DmoI and I-CreI subdomains. (a) Extrachromosomal assay in
CHO-K1 cells. Cells were transfected with diﬀerent meganucleases or
an empty vector and the cleavage against the two D2-Ca and
D(4AGT)-Ca (targets was measured). The nucleotides in the
D(4AGT)-Ca target for which the speciﬁcity has been modiﬁed have
been gray boxed. (b) Extrachromosomal assay in CHO-K1 cells. Cells
were transfected with diﬀerent meganucleases or an empty vector
(mock) and the cleavage against the two D2-Cb and D(4AGT)-Cb
targets was measured. The nucleotides in the D(4AGT)-Cb target for
which the speciﬁcity has been modiﬁed have been gray boxed.
Table 3. Cleavage activity in yeast of DmoCre variants with altered
speciﬁcity in both I-DmoI and I-CreI moieties
Library template
(target speciﬁcity)
Randomized
positions
Target tested Maximal cleavage
activity observed
in yeast (AU value)
Vb (D2-Cb) 75, 76, 77 D(4AGT)-Cb 0.91
D(4ATA)-Cb 0.57
D(4AGA)-Cb 0.66
D(4AGG)-Cb 0.50
29, 33, 35 D(10CTC)-Cb 0.19
D(10TAG)-Cb 0
D(10GCG)-Cb 0.64
D(10ACG)-Cb 0.64
D(10CCA)-Cb 0.41
Va (D2-Ca) 75, 76, 77 D(4AGT)-Ca 0.87
D(4ATA)-Ca 0
D(4AGA)-Ca 0.34
D(4AGG)-Ca 0.37
29, 33, 35 D(10CTC)-Ca 0
D(10TAG)-Ca 0
D(10GCG)-Ca 0.43
D(10ACG)-Ca 0
D(10CCA)-Ca 0.2
2014 Nucleic Acids Research, 2010,Vol.38, No. 6Ile229 belong to the protein hydrophobic core. In both
cases, the mutations consist in the replacement of one
hydrophobic residue with another hydrophobic residue
having a smaller side chain. Such a mutation could
slightly increase the protein ﬂexibility, which could
better accommodate its DNA target.
Finally, a set of DmoCre variants representative of each
engineering step (Va, Vb, S1, OM3 and OP2) (Figure 5)
were tested in a dose-response study (from 0.5 to 25ng of
meganuclease coding vectors) using an extrachromosomal
assay in CHO-K1 (19). We compared the cleavage
activities of several engineered DmoCre variants speciﬁc
to D2-Cb, D2Ca, D(4AGT)-C1, D(4AGT)-Ca and
D(4AGT)-Cb respectively, as well as the parental hybrid
DmoCreV5 molecule and the natural meganuclease I-SceI
against their cognate targets. Figure 5 shows that all of
the mutants are active in mammalian cells, however, the
DmoCre variants show less activity, compared to the
initial DmoCreV5 protein.
The engineered DmoCre mutants display a minimal
toxicity
The speciﬁcity/toxicity ratio is a crucial parameter in
DSB-induced recombination technology. Thus, the ﬁve
representative engineered meganucleases described above
(Va, Vb, S1, OM3 and OP2), along with the I-SceI and
DmoCreV5 meganucleases, were evaluated for their
potential toxicity using a cell survival assay in CHO-K1
cells (2). Two meganucleases derived from I-CreI were
added as control. The V2(G19S)/V3 (G19S) heterodimer
is an inactive meganuclease (2) while MegaX (4) is a
meganuclease with relaxed speciﬁcity. MegaX is a
heterodimeric meganuclease constituted by two I-CreI
mutants, which display a large cleavage proﬁle in a yeast
screening assay performed on several thousands of DNA
targets (data not shown). Figure 6a shows that the ﬁve
engineered DmoCre mutants, as well as the initial
DmoCreV5 protein, do not display any visible toxicity
and present the same proﬁle as I-SceI. As expected,
the inactive meganuclease shows a ﬂat pattern, while
expression of the non-speciﬁc MegaX induces signiﬁcant
toxicity.
Toxicity might be related to the speciﬁcity proﬁle of the
endonuclease, which may generate oﬀ-site cleavage events.
The characterization of the engineered DmoCre mutants
was completed by monitoring the g-H2AX foci content in
CHO-K1 cells, expressing the endonucleases, since the
g-H2AX focus formation is one the ﬁrst responses of the
cell to DNA DSBs. CHO-K1 cells were transfected
with 1mg of the expression vector for the diﬀerent
meganucleases carrying a C-terminal HA epitope. At
this high dose, no toxicity was revealed by the cell
survival assay. Expression of DmoCreV5, as well as the
ﬁve representative engineered DmoCre mutants, induces
on average, approximately two to three g-H2AX foci per
transfected cells, similar to the background level (expres-
sion of the inactive V2 (G19S)/V3 (G19S) meganuclease)
and to the number of foci induced by I-SceI (Figure 6b).
In contrast, the expression of the non-speciﬁc MegaX that
displayed toxicity in the cell survival assay induces an
average number of 12 g-H2AX foci per transfected cell.
Altogether, this data indicates that the modiﬁcation of the
protein speciﬁcity has not been achieved at the expense of
toxicity.
DISCUSSION
Double-strand break induced recombination technology
has proven to be an eﬃcient genome engineering
strategy. Moreover, recent advances in DNA-binding
protein engineering enabled scientists to alter the
speciﬁcity of such proteins in order to precisely target a
chosen locus in the genome (29,30). However, its applica-
tion in molecular medicine requires highly speciﬁc
reagents, capable to cleave a unique sequence in the
genome. In this regard, homing endonucleases and more
speciﬁcally, monomeric meganucleases present certain
advantages. The tight coupling of the binding site to
cleavage activity ensures a high degree of speciﬁcity and
minimal oﬀ-site target cleavage events. Moreover, in
contrast to zinc-ﬁnger nucleases or heterodimeric
meganucleases that need the coordinate expression of
two proteins, monomeric molecules simplify problems
related to the delivery and expression of the protein.
The fusion of protein domains is an important strategy
in both molecular evolution and protein engineering. In
this report we have explored the modularity properties of
a previously described chimeric meganuclease, DmoCre
(20). We show that the speciﬁcity of this monomeric
meganuclease could be diversiﬁed, and highly active engi-
neered DmoCre variants could be obtained while keeping
the non-toxic character of the original scaﬀold.
Production of hybrid meganucleases created by the
fusion of domains from two distinct LAGLIDADG
homing endonucleases is a powerful means to enrich the
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Figure 5. In vivo cleavage activity of diﬀerent engineered DmoCre
mutants monitored in an extrachromosomal SSA assay. CHO-K1
cells were transfected with increasing amounts of meganuclease expres-
sion vectors (from 0 to 25ng). Activity of the DmoCreV5 and I-SceI
proteins and the S1, Va, Vb, OM3 and OP2 DmoCre mutants was
monitored against their respective cognate targets, D2-C1, S1234,
D(AGT)-C1, D2-Ca, D2-Cb, D(4AGT)-Ca and D(4AGT)-Cb targets.
Nucleic Acids Research,2010, Vol.38, No. 6 2015collection of DNA sequences that can be targeted by
such endonucleases. In this sense, the DmoCre protein
appears to be a promising scaﬀold since numerous
I-CreI monomers with altered speciﬁcities have already
been obtained (17,18) and could, at least theoretically,
be inserted in this scaﬀold. However, the DmoCre
protein initially exhibited only residual activity at 37 C
because of the thermophilic origin of I-DmoI and there-
fore was not an appropriate tool for most of the genome
engineering applications. Mesophilic I-DmoI variants
have already been described (31). However, the mutations
isolated in the I-DmoI context did not have any impact on
the DmoCre activity level (data not shown). Therefore, an
engineering step was ﬁrst performed in order to obtain a
DmoCre variant active at 37 C. Two successive rounds of
random mutagenesis allowed us to isolate a mesophilic
DmoCre enzyme, presenting high cleavage activity in
yeast and CHO cells. The newly generated DmoCreV5
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Figure 6. Evaluation of the potential toxicity of the DmoCre meganucleases. (a) Toxicity of the DmoCre engineered meganucleases, as monitored by
a cell survival assay. Increasing amounts of meganuclease expression vector and a constant amount of plasmid encoding GFP were used to
cotransfect CHO-K1 cells. Cell survival is expressed as a percentage of cells expressing GFP 6 days after transfection as described in the
‘Materials and methods’ section. (b) The potential genotoxicity of the engineered DmoCre meganucleases was monitored by visualizing the formation
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C-terminal HA epitope. For each condition, the average number of g-H2AX foci per transfected cell (HA positive) was determined. Pictures below
are representative images of cells transfected with the DmoCreV5, OP2, V2 (G19S)/V3 (G19S), I-SceI and Mega X meganucleases: Green, HA
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2016 Nucleic Acids Research, 2010,Vol.38, No. 6protein has three mutations in comparison with the initial
DmoCre protein: L15Q, I19D and G20S. All three
mutated residues are located in the LAGLIDADG helix
of the I-DmoI moiety. Structure superimposition reveals
that the G20S mutation is the equivalent of the G19S
mutation that has been isolated and described on I-CreI
heterodimers (2). This mutation decreases or even
abolishes the activity of homodimers and increases
activity of the heterodimer when present in only one
monomer. In accordance with these data, the G20S
mutation present in the DmoCre protein strongly
enhances its activity. Interestingly, the introduction of
the glycine to serine substitution in the LAGLIDADG
helix of the I-CreI moiety had no eﬀect on the activity
of DmoCre (our unpublished data). The Ile19 residue of
I-DmoI superimposes with Asp18 of I-CreI. In the I-CreI
homodimer structure, Asp18 of one monomer makes a
hydrogen bond with Tyr12 of the second monomer.
Thus, it is possible that the I19D mutation creates a new
interaction between the I-DmoI and I-CreI moieties, con-
ferring a greater stability to the DmoCreV5 hybrid
protein. The impact of the L15Q mutation is more uncer-
tain. Inspection of the E-DreI structure indicates that the
residue Leu15 resides in a hydrophobic pocket of the
protein. Replacement of a hydrophobic leucine residue
by a polar glutamine residue in such an environment
should have a potentially adverse eﬀect. However, this
mutation is signiﬁcant, since the engineering of a
DmoCreV5 mutant carrying only the I19D and G20S
mutations, results in a meganuclease slightly less active
in our extrachromosomal assay in CHO-K1 cells.
Biochemical and biophysical characterization of this
mutant could be very valuable; however, the protein
proved to be insoluble in bacteria and could therefore
not be produced in suﬃcient amounts to allow in vitro
analyses.
To widen the number of DNA sequences that could be
targeted by DmoCre derivatives, the DmoCreV5 protein
was further engineered to modify its speciﬁcity. First, the
inter-domain modularity was investigated. We showed
that the assembly of the I-Dmo moiety with I-CreI
variants, previously isolated (17,18) was very eﬀective
and results in a highly active meganuclease. Next, we
tackled the engineering of the I-DmoI moiety. A close
inspection of the protein–DNA interactions of the
I-DmoI and E-DreI meganucleases (23,27) allowed us to
identify three potential subdomains necessary for protein–
DNA interactions. The sequence DNA corresponding to
D2 of the D2-C1 DNA target of DmoCre was separated
into three DNA triplets (D(10NNN)-C1, D(7NNN)-C1 or
D(4NNN)-C1). We obtained locally engineered DmoCre
variants that showed altered speciﬁcities toward the
D(10NNN)-C1 or D(4NNN)-C1 DNA triplets, whereas
no altered speciﬁcities toward the D7NNN-C1 DNA
triplet could be isolated by mutating the two arginine
residues at positions 37 and 81, which interact with this
central region. The I-DmoI structure shows that these two
amino acids are in an extended conformation to establish
six hydrogen bonds with bases at positions  7t o 5. Any
mutation will thus result in amino acids with a shorter side
chain that would be unable to interact with the DNA.
Moreover, the strong interaction of Arg37 and Arg81
with the DNA could also be responsible for the failure
in combining the two sets of mutations associated with
the D(10NNN)-C1 and D(4NNN)-C1 targets respectively,
and seems to be a stumbling block of the I-DmoI
intradomain modularity. Therefore one can envision that
a DmoCre variant with a modiﬁed speciﬁcity towards the
D(7NNN)-C1 target might improve this engineering
approach.
In conclusion, we have generated a DmoCre variant
able to induce eﬃcient gene conversion events in mamma-
lian cells. Moreover, target site diversiﬁcation could be
achieved since we successfully produced active, engineered
DmoCre mutants, with combined altered speciﬁcities for
both the I-DmoI and I-CreI moieties., In addition to
the obvious advantage of alleviating the need of coordi-
nate expression of two proteins to form active
heterodimers, our newly generated and engineered
versions of DmoCre, as the monomeric I-SceI or engi-
neered single-chain I-CreI meganucleases (2), appear to
present minimal toxicity in mammalian cells and therefore
qualify as new tools for targeted gene modiﬁcation in vivo.
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